ArticleClinical epigenetics2025
Epigenetic age acceleration and rheumatoid arthritis: an NHANES-based analysis and survival prediction models.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association between Modified Cardiometabolic Index and rheumatoid arthritis: the mediating role of phenotypic age acceleration.Clinical rheumatology · 2026Article
- Association between biological aging and clinical mortality among patients with rheumatoid arthritis.Clinical rheumatology · 2026Article
- Geroscience insights into difficult-to-treat rheumatoid arthritis: the role of unhealthy aging, comorbidity, and therapeutic complexity.GeroScience · 2026Review
- Cross-talk between aging resilience pathways and autoimmunity onset.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveEpigenetic aging has been confirmed to be associated with the pathogenesis of rheumatoid arthritis (RA), however, its role in the prognosis of RA remains unclear.
methodsIn this cross-sectional and prospective study, Epigenetic age and acceleration in participants of the National Health and Nutrition Examination Survey (NHANES) were calculated with Horvath's clock, Hannum's clock, PhenoAge, GrimAge, and GrimAge version 2 (GrimAge2). The association of epigenetic age and epigenetic age acceleration with the prevalence and overall mortality risk in RA was assessed with prediction models constructed.
resultsAccelerated epigenetic aging increased the risk of overall mortality in RA with hazard ratio of 1.075 (95% CI 1.043-1.107, p < 0.0001) for GrimAge2 acceleration (GrimAge2Accel) and 1.064 (1.032-1.098, p < 0.0001) for GrimAge acceleration (GrimAgeAccel). The GrimAge2Accel-based models, adjusted for a set of covariates composed of independent risk factors, excelled in predicting the 10 year and 20 year survival with area under curve of 0.760 (95% CI 0.621-0.898) and 0.823 (0.697-0.949), respectively.
conclusionEpigenetic aging may play a harmfully promotive role in the onset and progression of RA, and the GrimAge2Accel-based prediction models could effectively predict the survival of RA patients. Further research is needed to elucidate the underlying mechanisms and to explore the potential clinical implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.